HR+/HER2- Metastatic Breast Cancer: Current Practice, Open Questions, and Future Directions

Join us for this interactive symposium, where experts will discuss the evolving treatment paradigm in HR-positive/HER2-negative MBC, including the subtleties of optimal clinical application of CDK4/6 inhibitor therapy, the evolving role of PI3K pathway blockade, and how new strategies may affect management of these patients in the near future.

Held in conjunction with SABCS® 2018

Agenda

7:30 PM - 8:00 PM: Dinner and Registration

8:00 PM - 8:10 PM: Welcome and Introduction

8:10 PM - 8:40 PM: Current Practice: CDK4/6 Inhibitors in the Management of HR+/HER2- MBC Joyce O’Shaughnessy, MD

8:40 PM - 9:05 PM: Open Questions: The Evolving Role of PI3K Pathway Blockade in the Treatment of HR+/HER2- MBC Sara Hurvitz, MD, FACP

9:05 PM - 9:25 PM: Future Directions: Exploring the Next Frontier for HR+/HER2- MBC – Matthew P. Goetz, MD

9:25 PM - 9:30 PM: Final Panel Discussion and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Faculty
Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Women's Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Faculty
Sara Hurvitz, MD, FACP

Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

CME

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in selecting individualized treatment for patients with hormone receptor–positive breast cancer.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Discuss the mechanisms of endocrine resistance in breast cancer and the rationale for different therapeutic targets to overcome this resistance
  • Evaluate available clinical data on abemaciclib, palbociclib, and ribociclib as part of current treatment algorithms for patients with de novo or recurrent HR-positive, HER2-negative MBC
  • Describe current therapeutic strategies and ongoing clinical trials of novel CDK4/6 inhibitor–based combinations for both early-stage and HR-positive, HER2-negative MBC
  • Summarize promising investigational treatment options after disease progression on endocrine and/or CDK4/6 inhibitor–based therapy
  • Identify potential biomarkers of sensitivity to CDK4/6 inhibitors in patients with breast cancer
  • Manage toxicities specific to agents used in the treatment of HR-positive breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.